Table 1 Monoclonal antibodies for the treatment of solid tumors.
From: Recent Advances Relating to the Clinical Application of Naked Monoclonal Antibodies in Solid Tumors
MAb | Trade name | Molecular target | Tumor target | Status |
|---|---|---|---|---|
Trastuzumab | Herceptin | HER2/neu | Breast | FDA approved |
Cetuximab | Erbitux | EGFR | CRC, SCCHN, NSCLC | FDA approved for CRC, SCCHN; phase I/II for NSCLC |
Bevacizumab | Avastin | VEGF-A | CRC, NSCLC, breast, renal, pancreatic, prostatic, melanoma | FDA approved for CRC, NSCLC; phase II/III for others |
Panitumumab | Vectibix | EGFR | CRC, Renal | FDA approved for CRC; phase II/III for others |
Matuzumab | — | EGFR | Pancreatic, NSCLC, peritoneal | Phase I/II |
Nimotuzumab | TheraCIM | EGFR | SCCHN, NSCLC, glioma | Phase I/II |
MDX-447 | — | EGFR | SCCHN | Phase I/II |
Oregovomab | OvaRex | CA125 | Ovarian | Phase I/II |
Pertuzumab | — | EGFR | Ovarian, NSCLC, prostatic | Phase I/II |
Ipilimumab | — | CTLA-4 | Melanoma | Phase I/II |